188 related articles for article (PubMed ID: 10385711)
21. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
22. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.
Derwahl M; Hamacher C; Russo D; Broecker M; Manole D; Schatz H; Kopp P; Filetti S
J Clin Endocrinol Metab; 1996 May; 81(5):1898-904. PubMed ID: 8626855
[TBL] [Abstract][Full Text] [Related]
23. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
Persani L; Lania A; Alberti L; Romoli R; Mantovani G; Filetti S; Spada A; Conti M
J Clin Endocrinol Metab; 2000 Aug; 85(8):2872-8. PubMed ID: 10946896
[TBL] [Abstract][Full Text] [Related]
24. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
Derwahl M
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
[TBL] [Abstract][Full Text] [Related]
25. Pathology of the TSH receptor.
Duprez L; Parma J; Van Sande J; Rodien P; Sabine C; Abramowicz M; Dumont JE; Vassart G
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():295-302. PubMed ID: 10698593
[TBL] [Abstract][Full Text] [Related]
26. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions.
Arturi F; Scarpelli D; Coco A; Sacco R; Bruno R; Filetti S; Russo D
Thyroid; 2003 Apr; 13(4):341-3. PubMed ID: 12804102
[TBL] [Abstract][Full Text] [Related]
27. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
[TBL] [Abstract][Full Text] [Related]
28. Thyrotropin binding and adenylate cyclase stimulation in thyroid neoplasms.
Clark OH; Gerend PL; Cote TC; Nissenson RA
Surgery; 1981 Aug; 90(2):252-61. PubMed ID: 6266060
[TBL] [Abstract][Full Text] [Related]
29. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
Castro I; Lima L; Seoane R; Lado-Abeal J
Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
[TBL] [Abstract][Full Text] [Related]
30. [TSH receptors and signal transduction].
Kawakami Y; Fujita R; Okuda Y; Yamashita K
Nihon Rinsho; 1993 Oct; 51(10):2649-54. PubMed ID: 8254934
[TBL] [Abstract][Full Text] [Related]
31. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene.
Polak M
Arch Med Res; 1999; 30(6):510-3. PubMed ID: 10714365
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.
Duprez L; Parma J; Van Sande J; Allgeier A; Leclère J; Schvartz C; Delisle MJ; Decoulx M; Orgiazzi J; Dumont J
Nat Genet; 1994 Jul; 7(3):396-401. PubMed ID: 7920658
[TBL] [Abstract][Full Text] [Related]
33. Activation of the cAMP cascade in thyroid autonomy.
Paschke R
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S4-5. PubMed ID: 9867187
[No Abstract] [Full Text] [Related]
34. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis.
van Staveren WC; Solís DW; Delys L; Venet D; Cappello M; Andry G; Dumont JE; Libert F; Detours V; Maenhaut C
Proc Natl Acad Sci U S A; 2006 Jan; 103(2):413-8. PubMed ID: 16381821
[TBL] [Abstract][Full Text] [Related]
35. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations in thyroid hyperfunctioning adenomas.
Russo D; Arturi F; Wicker R; Chazenbalk GD; Schlumberger M; DuVillard JA; Caillou B; Monier R; Rapoport B; Filetti S
J Clin Endocrinol Metab; 1995 Apr; 80(4):1347-51. PubMed ID: 7714109
[TBL] [Abstract][Full Text] [Related]
37. gsp mutations in human thyroid tumours.
Suarez HG; du Villard JA; Caillou B; Schlumberger M; Parmentier C; Monier R
Oncogene; 1991 Apr; 6(4):677-9. PubMed ID: 1903197
[TBL] [Abstract][Full Text] [Related]
38. Genetic background of carcinogenesis in the thyroid gland.
Lewiński A; Wojciechowska K
Neuro Endocrinol Lett; 2007 Apr; 28(2):77-105. PubMed ID: 17435680
[TBL] [Abstract][Full Text] [Related]
39. [Transgenic mouse models. Their interest in thyroid tumors].
Ledent C; Franc B; Parmentier M
Arch Anat Cytol Pathol; 1998; 46(1-2):31-7. PubMed ID: 9754358
[TBL] [Abstract][Full Text] [Related]
40. Expression of cAMP-responsive element binding protein and inducible cAMP early repressor in hyperfunctioning thyroid adenomas.
Peri A; Luciani P; Tonacchera M; Agretti P; Baglioni-Peri S; Buci L; Conforti B; Cioppi F; Biliotti G; Serio M; Vitti P; Chiovato L
Eur J Endocrinol; 2002 Jun; 146(6):759-66. PubMed ID: 12039695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
